Rethinking Biotherapeutics
Mission
Eterna is unlocking the power of cell engineering for curative and transformative therapies.
Eterna is currently leveraging its proprietary IP portfolio, protected by over 100 patents and developed over the last 12 years, to co-develop novel assets with life sciences companies in the following areas:
Partner with us
Cell Reprogramming
Eterna technology uses mRNA to express reprogramming proteins, and can be leveraged for development of allogeneic pluripotent stem cell-derived CAR-T and CAR-NK cell therapies for the treatment of...
See More
Gene Editing
Eterna uses mRNA to express gene-editing proteins. Our proprietary gene-editing proteins including NoveSliceTM and UltraSliceTM are capable of deactivating, repairing, inserting, replacing, or...
See More
Gene Delivery
Eterna lipid nanoparticle (LNP) technology (e.g. ToRNAdoTM) enables efficient delivery of mRNA cargo safety into human cells and can be used in conjunction with our cell reprogramming technology....
See More
In Development
In addition to licensing our extensive patent portfolio to co-development partners, Eterna strives to develop therapeutic candidates in rare diseases, autoimmune diseases, and oncology.
News
February 20, 2024
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
January 3, 2024
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
Featured Publications
November 3, 2022
mRNA Cell Engineering Enables Rapid Prototyping of Macrophage Gene-Editing Strategies for Cancer Immunotherapy Applications
April 24, 2024
Directed Differentiation of Gene Edited iPSCs by Small-Molecule Inhibition of a Transgene-Encoded Protein